EyeCool Therapeutics Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Angel

  • Investors
  • 6

EyeCool Therapeutics General Information

Description

Developer of a novel device-based technology designed to focus on developing innovative treatments for Chronic Ocular Surface Pain (COSP). The company delivers a targeted, precise dose of thermal energy to transform the experience of COSP patients, and the product workflow integrates into current clinical workflows, ensuring efficient and effective patient care, enabling the healthcare industry to provide fast and lasting relief for patients suffering from this condition.

Contact Information

Website
www.eyecooltx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1000 Massachusetts Avenue
  • Suite 101
  • Cambridge, MA 02138
  • United States
Primary Industry
Therapeutic Devices
Other Industries
Drug Discovery
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • 1000 Massachusetts Avenue
  • Suite 101
  • Cambridge, MA 02138
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

EyeCool Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Angel (individual) 01-Dec-2024 Completed Startup
2. Early Stage VC 01-Mar-2022 Completed Stealth
1. Early Stage VC (Series A) 04-Jun-2021 $12.5M $12.5M Completed Stealth
To view EyeCool Therapeutics’s complete valuation and funding history, request access »

EyeCool Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A
To view EyeCool Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

EyeCool Therapeutics Patents

  • 20

    Total Documents Applications and Grants

  • Total Patents Families

  • 9

    Granted

  • 10

    Pending

  • Expiring in next 12 mo

EyeCool Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026102301-A1 Formulations, devices, and methods for lowering intraocular pressure Pending 07-Nov-2024
AU-2024213363-A1 Formulations, devices, and methods for alleviating symptoms of ocular surface discomfort Pending 03-Feb-2023
EP-4658192-A1 Formulations, devices, and methods for alleviating symptoms of ocular surface discomfort Pending 03-Feb-2023
US-12667482-B2 Formulations, devices, and methods for alleviating symptoms of ocular surface discomfort Active 03-Feb-2023
US-20250177199-A1 Formulations, devices, and methods for alleviating symptoms of ocular surface discomfort Active 03-Feb-2023 A61F7/10
To view EyeCool Therapeutics’s complete patent history, request access »

EyeCool Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

EyeCool Therapeutics Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Angel Physicians Fund Angel Group Minority
Hub Angels Investment Group Angel Group Minority
PV Capital Management Family Office Minority
Excelestar Ventures Venture Capital Minority
Catalyst Health Ventures Venture Capital Minority
You’re viewing 5 of 6 investors. Get the full list »

Ready to get started?

Request a free trial

EyeCool Therapeutics FAQs

  • When was EyeCool Therapeutics founded?

    EyeCool Therapeutics was founded in 2021.

  • Where is EyeCool Therapeutics headquartered?

    EyeCool Therapeutics is headquartered in Cambridge, MA.

  • What is the size of EyeCool Therapeutics?

    EyeCool Therapeutics has 10 total employees.

  • What industry is EyeCool Therapeutics in?

    EyeCool Therapeutics’s primary industry is Therapeutic Devices.

  • Is EyeCool Therapeutics a private or public company?

    EyeCool Therapeutics is a Private company.

  • What is EyeCool Therapeutics’s current revenue?

    The current revenue for EyeCool Therapeutics is .

  • How much funding has EyeCool Therapeutics raised over time?

    EyeCool Therapeutics has raised $12.5M.

  • Who are EyeCool Therapeutics’s investors?

    Angel Physicians Fund, Hub Angels Investment Group, PV Capital Management, Excelestar Ventures, and Catalyst Health Ventures are 5 of 6 investors who have invested in EyeCool Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process